Navigation Links
Takeda to Establish Four Sales and Marketing Subsidiaries to Expand Its Operations in Mexico, Turkey and Five Other Countries in Europe
Date:10/1/2009

ars. Takeda also recently re-acquired the rights to Actos in this market, providing the business with a strong product with which to enter the market.

Overall, the new subsidiaries will accelerate Takeda's expansion efforts for core products including Actos and reinforces Takeda's global operating infrastructure. The company will work toward the earliest possible approval and launch of new products in these regions. Takeda's presence in these seven new countries builds upon other expansions announced in 2009 including commercial operations in Spain, Portugal, Ireland, and Canada.

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Takeda is enhancing its R&D pipeline by concentrating its management resources in the following selected core therapeutic areas: lifestyle-related diseases, oncology and urological diseases (including gynecology), central nervous system diseases (including bone and joint disorders), and gastroenterological diseases. For more information, please visit http://www.takeda.com/.

About Takeda Pharmaceuticals Mexico, S.A. de C.V.

    Name:           Takeda Pharmaceuticals Mexico, S.A. de C.V.
    Location:      Mexico city, Mexico
    Established:  October 2009

About Takeda Pharmaceuticals Nordics AB

    Name:           Takeda Pharmaceuticals Nordics AB
    Location:      Sweden
    Established:  October 2009

About Takeda Pharmaceuticals Benelux SPRL

    Name:           Takeda Pharmaceuticals Benelux SPRL
    Location:      Belgium
    Established:  October 2009

About Takeda Pharmac
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
2. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
3. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
4. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
5. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
8. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
9. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
10. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
11. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 Nanomix Inc., (Nanomix), a ... of mobile diagnostic tests to enable earlier ... pre-hospital settings, today announced it has received ... certification was awarded by the British Standards ... certification bodies. ISO 13485:2003 ...
(Date:11/26/2014)... , Nov. 25, 2014 Amgen (NASDAQ: ... today announced that AMAGINE-2 TM , a pivotal, multi-arm Phase ... 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints ... at week 12. Brodalumab 210 mg given every two weeks ... be superior to Stelara on the primary endpoint of achieving ...
(Date:11/26/2014)... SHENZHEN, China, Nov. 26, 2014 China Nepstar ... the "Company"), a leading retail drugstore chain in China ... announced its unaudited financial results for the third quarter ... ended September 30, 2014: , Same store sales increased ... , Revenue increased by 8.1% to RMB738.3 million (US$120.3 ...
Breaking Medicine Technology:Nanomix Receives ISO 13485:2003 Certification 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 11
... 2011 Visionary Pharmaceuticals, Inc., announced today that ... a consortium of Angel Investors. The company is ... retinoic acid related orphan receptor (ROR) modulators targeting ... disorders including rheumatoid arthritis, multiple sclerosis, psoriasis and ...
... Ind., July 26, 2011 Symmetry Medical Inc. (NYSE: ... the global orthopaedic device industry and other medical markets, announced ... for the period ending July 2, 2011 before the market ... an accompanying conference call at 8:00 a.m. ET on Thursday, ...
Cached Medicine Technology:Visionary Pharmaceuticals, Inc., Announces Initial Seed Round Investments and the Launch of TH17 Autoimmune Disease Research Activities 2Symmetry Medical to Report Second Quarter 2011 Financial Results on August 4, 2011 2
(Date:11/27/2014)... Mission Viejo, CA, (PRWEB) November 26, 2014 ... premiered their browser-based presentation platform, focused on increasing ... produced by Britannic Technologies. Lintelus’ software platform includes ... the audience and presenter in a collaborative, interactive ... the meeting and the presentation in real time ...
(Date:11/26/2014)... CA (PRWEB) November 26, 2014 Healthpointe ... community of Perris , and it will be ... Campo specializes in the field of Occupational Medicine and ... Healthpointe’s Occupational Medicine specialist delivers quality care for employers ... safety and health. , As an Occupational ...
(Date:11/26/2014)... Sweetdressy.com, the well-known wedding dress manufacturer ... of cheap prom dresses for ladies worldwide. Meanwhile, these ... dresses from Sweetdressy.com are very popular in the world ... of Sweetdressy.com now. , Sweetdressy.com believes that a ... the best items and best services. The spirit of ...
(Date:11/26/2014)... Norwalk, Connecticut (PRWEB) November 27, 2014 ... has achieved Pathway to Excellence® designation by the ... to Excellence designation identifies the elements of work ... the professional satisfaction of nurses at Norwalk Hospital ... places to work. It identifies an organizations’ ...
(Date:11/26/2014)... News) -- When you,re planning your holiday get-away, ... vacation sports -- such as skiing or hiking, ... explorers may fail to take altitude into account ... at risk of developing fatigue and other symptoms ... to Dr. Melissa Tabor, an assistant professor of ...
Breaking Medicine News(10 mins):Health News:Lintelus Showcases its Feature-Rich Presentation Technology Solution at Convergence Summit’s Annual Event in London 2Health News:Healthpointe now offering Occupational Medicine in their Perris Medical Clinic 2Health News:Healthpointe now offering Occupational Medicine in their Perris Medical Clinic 3Health News:Cheap Prom Dresses For Ladies Introduced At SweetDressy.com 2Health News:Norwalk Hospital Announces American Nurses Credentialing Center PATHWAY TO EXCELLENCE® DESIGNATION 2Health News:Norwalk Hospital Announces American Nurses Credentialing Center PATHWAY TO EXCELLENCE® DESIGNATION 3Health News:Don't Let High Altitude Ruin Your Holiday Trip 2
... brain may have problems in forming perception categories for// printed ... to the dyslexics finding it difficult to filter out visual ... of them. ,The research by the scientists from University ... the nature of the workings of a dyslexic brain. ...
... to lose knee lubrication following an injury to the knee. ... University of Rhode Island had identified a way to find ... knee after a knee injury, in order to find out ... ,Although knee injury is considered to be a risk ...
... that children are more exposed to indoor allergens// at ... that are commonly found indoor include bacteria, molds, mildew, ... cockroaches and pollens. These may cause allergic reactions like ... Some of the symptoms experienced by people in presence ...
... survived cancer may have higher risks of having cognitive// ... University of Southern California had found that patients who ... twice as much risk as their healthy counterparts of ... survivors of cancer and their twins with the help ...
... Canada helped in conceiving and// delivering world’s first baby ... mother of the baby had her eggs collected from ... thawed and fertilized from sperms of her partner through ... was implanted in her uterus, which she carried to ...
... constantly exposed to air pollutions of big// cities may ... ,Inhalation of polluted air of the metros can ... particles emitted from the cars, trucks, buses, tobacco smoke, ... the chromosome of the fetus. , ,The research ...
Cached Medicine News:
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: